Taking these observations together, in a clinical translational view, suppressing the expression of HOXB7, HOXB9, HOXA11-AS, and microRNA-130a, or maintaining the expression of HOXA5 and microRNA-192, provides a potential therapeutic strategy to restrain tumor-associated angiogenesis and thus inhibit the growth of tumors. Here, HOXA5 is linked to neoplasm.